Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Video Expert Opinion
Round Table Discussions
Sign in
Join now
Lee Schwartzberg MD, FACP
Lee S. Schwartzberg MD, FACP Advisory Board
Annette Hasenburg Prof., Dr, med
Annette Hasenburg Prof., Dr, med Advisory Board
Jean-Yves Douillard MD, PhD
Jean-Yves Douillard MD, PhD Advisory Board
See All Experts
featured
Published in Oncology and
2 other channels

Expert Opinion / Conference Coverage · February 27, 2015

Controversy at ASCO GU: Conflicting Randomized Trials on Docetaxel Plus ADT for Hormone Sensitive Metastatic Prostate Cancer

Moshe Ornstein MD

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Moshe Ornstein MD

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading

Most Read This Week

Recently Updated